Actelion Pharmaceuticals Competitors and Similar CompaniesClear all

Actelion Pharmaceuticals's competitors and similar companies include Evotec, UCB and Genentech.

	Actelion Pharmaceuticals Actelion Pharmaceuticals is a biopharmaceutical company focusing on the discovery, development, and commercialization of innovative treatments to serve high unmet medical needs.	Evotec Evotec is a biotechnology company that provides drug discovery and development services.	UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.	Genentech Genentech is a biotechnology company that discovers, develops, manufactures, and commercializes medicines.
Founding Date	Founding Date 1997	Founding Date 1993	Founding Date 1928	Founding Date 1976
Type	Type Subsidiary	Type Public	Type Public	Type Subsidiary
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development oncology pharma
Locations	Locations Allschwil, CH HQ Belrose, AU Mechelen, BE Laval, CA see more	Locations Hamburg, DE HQ Lyon, FR Toulouse, FR Göttingen, DE Halle (Westfalen), DE Köln, DE Munich, DE see more	Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more	Locations South San Francisco, US HQ Hillsboro, US Oceanside, US Portland, US South San Francisco, US South San Francisco, US South San Francisco, US see more
Employees	Employees 51712% decrease	Employees 4,766	Employees 9,052	Employees 18,077
Valuation ($)	Valuation ($) N/A	Valuation ($) 1.4 b	Valuation ($) 34.3 b	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) N/A	Revenue (est.) €788.4m (FY, 2025)	Revenue (est.) €7.4b (FY, 2025)	Revenue (est.) N/A
Cost of goods	Cost of goods N/A	Cost of goods €622.9m (FY, 2025)	Cost of goods €1.4b (FY, 2025)	Cost of goods N/A
Gross profit	Gross profit N/A	Gross profit €231.1m (FY, 2025)	Gross profit €7.2b (FY, 2025)	Gross profit N/A
Net income	Net income N/A	Net income (€103.5m) (FY, 2025)	Net income €1.6b (FY, 2025)	Net income N/A